Amyris, Inc. (NASDAQ:AMRS) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01 Change in Registrants Certifying Accountant.
On June 9, 2017, PricewaterhouseCoopers LLP
(PwC) notified Amyris, Inc. (the
Company) that it declined to stand for
re-election as the independent registered public accounting firm
for the Company. The Audit Committee (the Audit
Committee) of the Board of Directors of the Company
has been conducting a competitive process to determine the
Companys independent registered public accounting firm for its
2017 fiscal year. The Audit Committee invited three national
accounting firms to participate in this process, and expects to
complete the process and engage a new independent registered
accounting firm next week.
PwCs audit reports on the Companys consolidated financial
statements for the fiscal years ended December 31, 2016 and 2015
contained no adverse opinion or disclaimer of opinion and were
not qualified or modified as to uncertainty, audit scope, or
accounting principles, except that PwCs reports for the fiscal
years ended December 31, 2016, and December 31, 2015 included an
explanatory paragraph indicating that there was substantial doubt
about the Companys ability to continue as a going concern.
During the Companys two most recent fiscal years, which ended
December 31, 2016 and December 31, 2015, and the subsequent
interim period through June 9, 2017, (i) there were no
disagreements (within the meaning set forth in Item 304(a)(1)(iv)
of Regulation S-K) with PwC on any matter of accounting
principles or practices, financial statement disclosure, or
auditing scope or procedure, which disagreements, if not resolved
to PwCs satisfaction, would have caused PwC to make reference to
the subject matter of the disagreements in their reports on the
Companys consolidated financial statements for such years; and
(ii) there were no reportable events (within the meaning set
forth in Item 304(a)(1)(v) of Regulation S-K).
In accordance with Item 304(a)(3) of Regulation S-K, the Company
has requested that PwC furnish it with a letter addressed to the
United States Securities and Exchange Commission stating whether
or not PwC agrees with above statements of the Company in this
Item 4.01. PwC furnished the requested letter, stating its
agreement with such statements, and a copy is filed as Exhibit
16.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description | |
| 16.1 | Letter of PricewaterhouseCoopers LLP dated June 15, 2017 |
About Amyris, Inc. (NASDAQ:AMRS)
Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.
